Results 151 to 160 of about 17,377 (218)

3 Discordant Extracardiac Amyloid Proteins Highlighting Bystander Deposition in a Case of Light-Chain Amyloid Cardiomyopathy. [PDF]

JACC Case Rep
Coderre R, Tersalvi G, Adigun RO, Boilson BA, Borgeson DD, Clavell AL, Chang IC, Abdallah NH, Grogan M, AbouEzzeddine OF.   +9 more
europepmc   +1 more source

Functional Stability Measured by Changes in the 6-min Walk Test in Patients Treated with Tafamidis Versus Placebo: Post hoc Analysis from ATTR-ACT. [PDF]

Cardiol Ther
Witteles R, Hanna MA, Grogan M, Elliott P, Wang R, Garcia-Pavia P.   +5 more
europepmc   +1 more source

Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients with Transthyretin Amyloid Cardiomyopathy. [PDF]

Cardiol Ther
Fumagalli C, Cappelli F, Maurer MS, Aus dem Siepen F, Dispenzieri A, Garcia-Pavia P, Hanna M, Carlsson M, Damy T.   +8 more
europepmc   +1 more source

The Red Flags Were Missing, the Indication Was Not: Genetic Testing in Heart Failure and Cardiomyopathy. [PDF]

Methodist Debakey Cardiovasc J
Bakr Salama A.
europepmc   +1 more source

Transthyretin Kinetic Stabilizers for ATTR Amyloidosis

Cardiology and Therapy
openaire   +2 more sources

Survival in a Contemporary, Real-World, Matched Cohort of Patients with Transthyretin Amyloid Cardiomyopathy Treated vs Not Treated with Tafamidis. [PDF]

Cardiol Ther
Aus dem Siepen F, Dispenzieri A, Hanna M, Carlsson M, Garcia-Pavia P.   +4 more
europepmc   +1 more source

First clinical experience with the Transthyretin Amyloidosis-Quality of Life questionnaire (ATTR-QoL): associations with clinical characteristics and established patient-reported outcomes. [PDF]

Eur Heart J Qual Care Clin Outcomes
Bampatsias D, Teruya S, Mirabal Santos A, Levy JC, Hsu K, Johnson PT, Rebello S, Lovley A, LaGasse K, McCausland KL, Wats K, Maurer MS.   +11 more
europepmc   +1 more source